View Older Stories View More Recent Stories
-
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals
-
STOCKHOLDER ALERT: Pending Securities Fraud Lawsuit Against Regeneron Pharmaceuticals (REGN)
-
REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
Regeneron Pharma (REGN) PT Lowered to $950 at Oppenheimer
-
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals
-
Regeneron Pharma (REGN) PT Lowered to $1,184 at RBC Capital
-
RBC report: Biotech faces both uncertainty and growth opportunities in 2025
-
RBC Capital's Game Changers: 'Disruptive Forces in Biotech'
-
Regeneron (REGN) to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results
-
Regeneron (REGN) Reports EYLEA HD Injection 8 mg Phase 3 Trial Meets Primary Endpoint
-
RBC Capital's Global Biotech Outlook Report: 'Top 2025 Ideas'
-
Truist: 'Potential Impact of Trump's Nominees on Biopharma'
-
Piper Sandler on Regeneron Pharma (REGN): 'Eylea-HD Conversion Slow and Steady'
-
Here are the key catalysts for 3 US biotech stocks into year end
-
Citi Starts Regeneron Pharma (REGN) at Neutral
-
TD Cowen Reiterates Buy Rating on Regeneron Pharma (REGN)
-
Regeneron Pharma (REGN) PT Lowered to $1,190 at BMO Capital
-
Regeneron Pharma (REGN) PT Lowered to $1,195 at Piper Sandler
-
Regeneron Pharma (REGN) PT Lowered to $880 at Leerink Partners
-
Regeneron (REGN) Files Mixed Shelf
-
Regeneron Pharma (REGN) PT Lowered to $1,170 at Evercore ISI
-
Regeneron (REGN) Tops Q3 EPS by 74c
-
Piper Sandler Reiterates Overweight Rating on Regeneron Pharma (REGN)
-
Regeneron (REGN): Dupixent Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI
-
Regeneron Pharma (REGN) PT Lowered to $1,175 at Evercore ISI
-
TD Cowen Reiterates Buy Rating on Regeneron Pharma (REGN)
-
Regeneron Pharma (REGN) PT Lowered to $1,050 at Wells Fargo
-
Amgen (AMGN) Launches Pavblu As Rival To Regeneron's (REGN) Eylea - Bloomberg
-
Regeneron (REGN) Weakness Tied to Report Court Rejects Request for Injunction for Eylea Generic
-
Regeneron (REGN) Reports Three-year Results for EYLEA HD Injection 8 mg
-
Regeneron Pharma (REGN) PT Lowered to $1,137 at Truist Securities
-
BMO Capital Reiterates Outperform Rating on Regeneron Pharma (REGN)
-
Erste Group Downgrades Regeneron Pharma (REGN) to Hold, 'sales growth will be impaired'
-
TD Cowen Reiterates Buy Rating on Regeneron Pharma (REGN)
-
TD Cowen Reiterates Buy Rating on Regeneron Pharma (REGN)
-
Regeneron (REGN): Dupixent Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease
-
Morgan Stanley Reiterates Overweight Rating on Regeneron Pharma (REGN)
-
Piper Sandler Reiterates Overweight Rating on Regeneron Pharma (REGN)
-
Piper Sandler are buyers of this biotech stock despite ongoing selloff
-
Truist Securities on Regeneron Pharma (REGN): 'Buying opportunity'
-
Leerink Partners Downgrades Regeneron Pharma (REGN) to Market Perform, 'Eylea Franchise Outlook Uncertain'
-
Baird Reiterates Neutral Rating on Regeneron Pharma (REGN)
-
Goldman Sachs Reiterates Buy Rating on Regeneron Pharma (REGN)
-
RBC Capital on Regeneron (REGN): 'We see potential earlier-than-expected launch of biosimilar product as incrementally negative to REGN's story'
-
BMO Capital Reiterates Outperform Rating on Regeneron Pharma (REGN)
-
Truist Securities on Regeneron Pharma (REGN): 'view the pressure on stock as an overreaction'
-
Regeneron (REGN) Reports Dupixent Recommended for EU Approval by the CHMP
-
BMO Capital Reiterates Outperform Rating on Regeneron Pharma (REGN)
-
Regeneron (REGN): Dupixent Approved in U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
-
BMO Capital Reiterates Outperform Rating on Regeneron Pharma (REGN)
